SOMNOMED LIMITED (SOM)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SOM - SOMNOMED LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 22.51
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.35

24 Jul
2024

0.020

OPEN

$0.34

6.06%

HIGH

$0.38

38,339

LOW

$0.34

OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . TRJ . UBI . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-7.5
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx83.6 M
Book Value Per Share xxxxxxxxxxxxxxx20.0
Net Operating Cash Flow xxxxxxxxxxxxxxx-3.9 M
Net Profit Margin xxxxxxxxxxxxxxx-9.41 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-31.35 %
Return on Invested Capital xxxxxxxxxxxxxxx-20.57 %
Return on Assets xxxxxxxxxxxxxxx-13.05 %
Return on Equity xxxxxxxxxxxxxxx-31.35 %
Return on Total Capital xxxxxxxxxxxxxxx-9.50 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-7.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx3 M
Long Term Debt xxxxxxxxxxxxxxx21 M
Total Debt xxxxxxxxxxxxxxx24 M
Goodwill - Gross xxxxxxxxxxxxxxx6 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx12 M
Price To Book Value xxxxxxxxxxxxxxx3.53

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx6.4 M
Capex % of Sales xxxxxxxxxxxxxxx7.67 %
Cost of Goods Sold xxxxxxxxxxxxxxx38 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx50 M
Research & Development xxxxxxxxxxxxxxx1 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

10/05/2024

3

Market Weight

$0.23

-34.29%

Wilsons maintains a Market Weight rating on SomnoMed with a revised target price of $0.23, down from $0.45.

This adjustment is prompted by an operational review revealing capacity constraints, leading to a guidance downgrade and a capital raising.

The broker explains funds raised are intended to clear debt, invest in manufacturing, and stabilise the core business before launching RestAssure, a new 'connected care' platform for oral appliance sleep apnoea therapy.

FORECAST
Wilsons forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -4.80 cents.
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -1.70 cents.

SOM STOCK CHART